204 related articles for article (PubMed ID: 33402021)
1. Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment.
Aspirin AP; de Los Reyes V AA; Kim Y
J R Soc Interface; 2021 Jan; 18(174):20200669. PubMed ID: 33402021
[TBL] [Abstract][Full Text] [Related]
2. Optimal strategies of oncolytic virus-bortezomib therapy via the apoptotic, necroptotic, and oncolysis signaling network.
Lee D; V AALR; Kim Y
Math Biosci Eng; 2024 Feb; 21(3):3876-3909. PubMed ID: 38549312
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
4. Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.
Kim Y; Yoo JY; Lee TJ; Liu J; Yu J; Caligiuri MA; Kaur B; Friedman A
Proc Natl Acad Sci U S A; 2018 May; 115(19):4927-4932. PubMed ID: 29686060
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model.
Senekal NS; Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
Bull Math Biol; 2021 May; 83(7):75. PubMed ID: 34008149
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.
Suryadevara CM; Riccione KA; Sampson JH
Clin Cancer Res; 2016 Nov; 22(21):5164-5166. PubMed ID: 27521450
[TBL] [Abstract][Full Text] [Related]
7. The two-faces of NK cells in oncolytic virotherapy.
Marotel M; Hasim MS; Hagerman A; Ardolino M
Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
[TBL] [Abstract][Full Text] [Related]
8. Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells.
Leung EYL; McNeish IA
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452316
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
Front Immunol; 2022; 13():950079. PubMed ID: 36703982
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
11. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
12. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
Nistal-Villan E; Bunuales M; Poutou J; Gonzalez-Aparicio M; Bravo-Perez C; Quetglas JI; Carte B; Gonzalez-Aseguinolaza G; Prieto J; Larrea E; Hernandez-Alcoceba R
Mol Cancer; 2015 Dec; 14():210. PubMed ID: 26671477
[TBL] [Abstract][Full Text] [Related]
13. Targeting autophagy to enhance oncolytic virus-based cancer therapy.
Meng S; Xu J; Wu Y; Ding C
Expert Opin Biol Ther; 2013 Jun; 13(6):863-73. PubMed ID: 23488666
[TBL] [Abstract][Full Text] [Related]
14. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
15. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
16. Combining oncolytic virotherapy and cytotoxic therapies to fight cancer.
Fillat C; Maliandi MV; Mato-Berciano A; Alemany R
Curr Pharm Des; 2014; 20(42):6513-21. PubMed ID: 25341928
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
[TBL] [Abstract][Full Text] [Related]
18. Targeting proteasome enhances anticancer activity of oncolytic HSV-1 in colorectal cancer.
Li X; Hu W; Shen J; Li M; Gong W
Virology; 2023 Jan; 578():13-21. PubMed ID: 36434905
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of the IRE1α-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1.
Li K; Hu C; Xing F; Gao M; Liang J; Xiao X; Cai J; Tan Y; Hu J; Zhu W; Yin W; Li Y; Chen W; Lu B; Mai J; Qiu P; Su X; Yan G; Zhang H; Lin Y
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263275
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of Natural killer cells in oncolytic virotherapy.
Bhat R; Rommelaere J
Immunotargets Ther; 2015; 4():65-77. PubMed ID: 27471713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
